CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Identifieur interne : 001819 ( PubMed/Corpus ); précédent : 001818; suivant : 001820CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Auteurs : O. Rascol ; N. Fabre ; H. Ter V Inen ; W. Poewe ; C. Lücking ; U. Rinne ; E. Dupont ; D. Hirt ; M. Hoyer ; X. LatasteSource :
- Clinical neuropharmacology [ 0362-5664 ] ; 1990.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Drug Therapy, Combination, Ergolines (administration & dosage), Ergolines (adverse effects), Ergolines (therapeutic use), Female, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Ergolines, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Ergolines.
- chemical , therapeutic use : Antiparkinson Agents, Ergolines, Levodopa.
- drug therapy : Parkinson Disease.
- Aged, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
The antiparkinsonian efficacy and tolerability of CQA 206-291, a novel ergoline derivative with potent dopamine agonist properties, were studied during 2 months of treatment in 72 parkinsonian patients. In 36 de novo patients (patients who have not previously been treated with levodopa or dopamine agonists), CQA 206-291 was studied in an open design, while in 36 levodopa-treated patients, CQA 206-291 was studied in a randomized, double-blind, parallel-group, placebo-controlled design. CQA 206-291 induced in both groups a significant antiparkinsonian effect with an effective dose range of 5-30 mg/day. The spectrum of adverse events was similar to what is commonly observed with dopamine agonists. Further studies are required to assess the putative therapeutic advantages of CQA 206-291 when compared to other antiparkinsonian drugs.
PubMed: 2208182
Links to Exploration step
pubmed:2208182Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation><nlm:affiliation>Department of Medical and Clinical Pharmacology, INSERM U317, Toulouse, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name>
</author>
<author><name sortKey="Ter V Inen, H" sort="Ter V Inen, H" uniqKey="Ter V Inen H" first="H" last="Ter V Inen">H. Ter V Inen</name>
</author>
<author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W" last="Poewe">W. Poewe</name>
</author>
<author><name sortKey="Lucking, C" sort="Lucking, C" uniqKey="Lucking C" first="C" last="Lücking">C. Lücking</name>
</author>
<author><name sortKey="Rinne, U" sort="Rinne, U" uniqKey="Rinne U" first="U" last="Rinne">U. Rinne</name>
</author>
<author><name sortKey="Dupont, E" sort="Dupont, E" uniqKey="Dupont E" first="E" last="Dupont">E. Dupont</name>
</author>
<author><name sortKey="Hirt, D" sort="Hirt, D" uniqKey="Hirt D" first="D" last="Hirt">D. Hirt</name>
</author>
<author><name sortKey="Hoyer, M" sort="Hoyer, M" uniqKey="Hoyer M" first="M" last="Hoyer">M. Hoyer</name>
</author>
<author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X" last="Lataste">X. Lataste</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2208182</idno>
<idno type="pmid">2208182</idno>
<idno type="wicri:Area/PubMed/Corpus">001819</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001819</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation><nlm:affiliation>Department of Medical and Clinical Pharmacology, INSERM U317, Toulouse, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name>
</author>
<author><name sortKey="Ter V Inen, H" sort="Ter V Inen, H" uniqKey="Ter V Inen H" first="H" last="Ter V Inen">H. Ter V Inen</name>
</author>
<author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W" last="Poewe">W. Poewe</name>
</author>
<author><name sortKey="Lucking, C" sort="Lucking, C" uniqKey="Lucking C" first="C" last="Lücking">C. Lücking</name>
</author>
<author><name sortKey="Rinne, U" sort="Rinne, U" uniqKey="Rinne U" first="U" last="Rinne">U. Rinne</name>
</author>
<author><name sortKey="Dupont, E" sort="Dupont, E" uniqKey="Dupont E" first="E" last="Dupont">E. Dupont</name>
</author>
<author><name sortKey="Hirt, D" sort="Hirt, D" uniqKey="Hirt D" first="D" last="Hirt">D. Hirt</name>
</author>
<author><name sortKey="Hoyer, M" sort="Hoyer, M" uniqKey="Hoyer M" first="M" last="Hoyer">M. Hoyer</name>
</author>
<author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X" last="Lataste">X. Lataste</name>
</author>
</analytic>
<series><title level="j">Clinical neuropharmacology</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Ergolines (administration & dosage)</term>
<term>Ergolines (adverse effects)</term>
<term>Ergolines (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The antiparkinsonian efficacy and tolerability of CQA 206-291, a novel ergoline derivative with potent dopamine agonist properties, were studied during 2 months of treatment in 72 parkinsonian patients. In 36 de novo patients (patients who have not previously been treated with levodopa or dopamine agonists), CQA 206-291 was studied in an open design, while in 36 levodopa-treated patients, CQA 206-291 was studied in a randomized, double-blind, parallel-group, placebo-controlled design. CQA 206-291 induced in both groups a significant antiparkinsonian effect with an effective dose range of 5-30 mg/day. The spectrum of adverse events was similar to what is commonly observed with dopamine agonists. Further studies are required to assess the putative therapeutic advantages of CQA 206-291 when compared to other antiparkinsonian drugs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2208182</PMID>
<DateCreated><Year>1990</Year>
<Month>11</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted><Year>1990</Year>
<Month>11</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>4</Issue>
<PubDate><Year>1990</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Clinical neuropharmacology</Title>
<ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>303-11</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The antiparkinsonian efficacy and tolerability of CQA 206-291, a novel ergoline derivative with potent dopamine agonist properties, were studied during 2 months of treatment in 72 parkinsonian patients. In 36 de novo patients (patients who have not previously been treated with levodopa or dopamine agonists), CQA 206-291 was studied in an open design, while in 36 levodopa-treated patients, CQA 206-291 was studied in a randomized, double-blind, parallel-group, placebo-controlled design. CQA 206-291 induced in both groups a significant antiparkinsonian effect with an effective dose range of 5-30 mg/day. The spectrum of adverse events was similar to what is commonly observed with dopamine agonists. Further studies are required to assess the putative therapeutic advantages of CQA 206-291 when compared to other antiparkinsonian drugs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Clinical Pharmacology, INSERM U317, Toulouse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fabre</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Teräväinen</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Poewe</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lücking</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rinne</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dupont</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hirt</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hoyer</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lataste</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Neuropharmacol</MedlineTA>
<NlmUniqueID>7607910</NlmUniqueID>
<ISSNLinking>0362-5664</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>93822-42-5</RegistryNumber>
<NameOfSubstance UI="C059483">CQA 206-291</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004873" MajorTopicYN="N">Ergolines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year>
<Month>8</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1990</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1990</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">2208182</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001819 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001819 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:2208182 |texte= CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:2208182" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |